|J. Michael Walsh, Ph.D.
Dr. Walsh is the President of The Walsh
Group, P.A., a research and consulting firm located in Bethesda, Maryland. The Walsh
Group specialists provide consulting services and conduct research in substance abuse
policy and technology development.
From 1989-1993, Dr. Walsh served at the White House as the Executive Director of the
President’s Drug Advisory Council in the Executive Office of the President. He also
acted as the Associate Director of the Office of National Drug Control Policy (ONDCP)
until July 1993.
Prior to his White House appointment (1980-1989), he was Director of the Division of
Applied Research at the National Institute on Drug Abuse (NIDA) in the U.S. Department of
Health and Human Services. At NIDA, he directed national research programs including
drug policy, drug effects on performance/driving, drug testing, employee assistance
programs, and AIDS treatment research. Dr. Walsh led the task force that developed
the U.S. Federal Drug Testing Guidelines; he established and directed the National
Laboratory Certification Program and was responsible for coordinating the development of
all Federal Agency drug policies and programs.
Prior to his appointment at NIDA, Dr. Walsh was a civilian scientist at the Naval
Medical Research Institute in Bethesda, Maryland, where from 1966-1980 he conducted
biomedical research examining the effects of drugs on human performance in the areas of
psychopharmacology, behavioral toxicology, and hyperbaric medicine.
Dr. Walsh received his doctoral degree in psychology from the American University in
1973, and is licensed to practice in the State of Maryland.
Dr. Walsh has published more than 70 articles including books, chapters, and research
publications. He has been an invited speaker at national meetings, appeared on TV
news and commentary (including Nightline, CBS Evening News with Dan Rather, ABC World
News with Peter Jennings, NBC News with Tom Brokaw), and has been a witness before
Congressional committees on both the U.S. Senate and House of Representatives to provide
expert testimony on issues relating to the effects of drugs on performance and safety,
drug testing, laboratory certification, and workplace drug policy.